Psychedelics MindMed announces initial patient dosing in MM-120 study Biopharmaceutical company administers optimized form of LSD in Phase 2b dose-optimization trial Rowan DunneAugust 25, 2022
Cannabis Cannabis and psychedelic use among young people reaches all-time high in 2021: NIH Monitoring the Future panel study supported by the NIH outlines new statistics Rowan DunneAugust 24, 2022
International Mind Medicine Australia receives AUD$1M grant for psychedelic research New fund will support studies on psychedelic-assisted therapies for the treatment of mental health conditions Rowan DunneAugust 23, 2022
Canada PharmAla Biotech becomes first public company producing GMP MDMA Biotechnology organization will also supply LaNeo product to Australian research institute for clinical trial Rowan DunneAugust 22, 2022
Research ‘Hallucinogen’ use continues to rise: Columbia University New research estimates that over 5.5 million American adults used psychoactive substances in 2019 Rowan DunneAugust 22, 2022
Psychedelics Phillips Lytle announces the inception of its Psychedelic & Mental Health Therapies Practice New York law firm forms multidisciplinary association intended to serve the psychedelic industry Rowan DunneAugust 19, 2022
Cannabis Cybin receives Schedule I DEA license for CYB003 trial New license is the final required step before administering doses to study participants Rowan DunneAugust 17, 2022
Stock News Reunion Neuroscience starts trading on the TSX Reunion still holds 21.84% interest in Field Trip Health & Wellness Rowan DunneAugust 17, 2022
Canada Optimi receives amendment from Health Canada permitting MDMA production Vancouver producer to supply synthetic psychedelic compounds to designated investigators and companies Rowan DunneAugust 16, 2022
International Short Wave and Sheba partner for clinical trial aimed at combatting anorexia Innovative new studies in the Middle East receive approval from Israeli Ministry of Health Rowan DunneAugust 15, 2022